We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

85 hedge funds and large institutions have $123M invested in Antares Pharma, Inc. in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less funds holding

Funds holding: 91 → 85 (-6)

13% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 31

29% less capital invested

Capital invested by funds: $174M → $123M (-$51.1M)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

92% less call options, than puts

Call options by funds: $41K | Put options by funds: $498K

Holders
85
Holders Change
-6
Holders Change %
-6.59%
% of All Funds
2.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
27
Reduced
31
Closed
15
Calls
$41K
Puts
$498K
Net Calls
-$457K
Net Calls Change
-$882K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$5.48M
2
WHI
William Harris Investors
Illinois
+$2.48M
3
BC
Broadfin Capital
New York
+$2.26M
4
ACM
Ashford Capital Management
Delaware
+$687K
5
Citadel Advisors
Citadel Advisors
Florida
+$355K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$11.2M
2
Allianz Asset Management
Allianz Asset Management
Germany
-$4.32M
3
JGC
J. Goldman & Co
New York
-$3.41M
4
PWAM
Park West Asset Management
California
-$1.75M
5
KCM
Kingdon Capital Management
New York
-$978K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$25.6M +$347K +115,242 +1%
Millennium Management
2
Millennium Management
New York
$10.9M +$5.48M +1,820,865 +81%
BIT
3
BlackRock Institutional Trust
California
$10.7M -$208K -68,958 -2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$10.3M +$317K +105,274 +3%
BC
5
Broadfin Capital
New York
$8.14M +$2.26M +750,000 +33%
BFA
6
BlackRock Fund Advisors
California
$7.74M -$823K -273,537 -9%
WHI
7
William Harris Investors
Illinois
$6.24M +$2.48M +825,000 +55%
State Street
8
State Street
Massachusetts
$5.35M -$412 -137 -0%
Northern Trust
9
Northern Trust
Illinois
$3.51M -$465K -154,603 -11%
KCM
10
Kingdon Capital Management
New York
$3.1M -$978K -325,000 -22%
ACM
11
Ashford Capital Management
Delaware
$2.91M +$687K +228,100 +27%
PI
12
Putnam Investments
Massachusetts
$2.86M +$1.12K +372 +0%
UBS AM
13
UBS AM
Illinois
$2.73M -$320K -106,300 -9%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$2.54M +$82.1K +27,294 +3%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.71M +$21K +6,985 +1%
TCIM
16
TIAA CREF Investment Management
New York
$1.22M +$56.8K +18,872 +4%
Allianz Asset Management
17
Allianz Asset Management
Germany
$1.07M -$4.32M -1,435,234 -78%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$967K – – –
AC
19
Avenir Corporation
Virginia
$911K +$6.92K +2,300 +0.7%
BIM
20
BlackRock Investment Management
Delaware
$900K +$74.2K +24,665 +8%
MWR
21
McAdams Wright Ragen
Washington
$816K +$125K +41,666 +16%
CCM
22
Cadence Capital Management
Massachusetts
$812K -$101K -33,447 -10%
MIG
23
Mariner Investment Group
New York
$792K – – –
CIBC Private Wealth Group
24
CIBC Private Wealth Group
Georgia
$740K – – –
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$703K +$199K +66,000 +33%
1
2 3 4

ATRS Hedge Fund Activity: Q2 2014 in Review

85 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2014, worth a combined $123M — down 29% from $174M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of ATRS and 9 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 27 added.

The largest buyer was Millennium Management, adding an estimated $5.48M. The largest seller was OrbiMed, exiting entirely with an estimated $11.2M sold.

  • 85 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2014, down from 91 in Q1 2014.
  • Funds reported $123M of Antares Pharma, Inc. stock for Q2 2014, down 29% quarter-over-quarter.
  • 9 funds opened new Antares Pharma, Inc. positions in Q2 2014 and 15 closed out, a net change of -6 holders.
  • The largest Antares Pharma, Inc. buyer in Q2 2014 was Millennium Management, an estimated $5.48M added.
  • The largest Antares Pharma, Inc. seller in Q2 2014 was OrbiMed, an estimated $11.2M sold.

Based on aggregated 13F filings for Q2 2014.